Top entities: Ardelyx, Levi & Korsinsky, XPHOZAH, Joseph E. Levi.

What category does this event fall under?

Regulatory — classified as securities investigation.

What is the sentiment of coverage?

Aggregate sentiment score: -40 on a -100 to +100 scale (negative = critical coverage, positive = favorable coverage).

What were the key actions taken?

Ardelyx lowered revenue guidance · Ardelyx scheduled earnings call · Ardelyx withdrew revenue target

Is this event still developing?

This is an active story, last updated Aug 20, 2026. Coverage continues to evolve.

Regulatory securities investigation

Ardelyx guidance cut triggers securities investigation

Q: When did this event occur?

First reported Aug 14, 2026; last updated Aug 20, 2026.

Q: What is the market impact?

General. Ardelyx's stock dropped nearly 18% after the guidance cut, reflecting investor disappointment and eroding market confidence.

Analysis based on 6 articles · First reported Aug 14, 2026 · Last updated Aug 20, 2026

Sentiment

-40

Attention

Articles

Market Impact

General

Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard

Market Impact

Ardelyx's stock dropped nearly 18% after the guidance cut, reflecting investor disappointment and eroding market confidence. The securities investigation adds legal and reputational risk, potentially pressuring the stock further and raising costs for the company.

Biotechnology Pharmaceuticals

Event Summary

Ardelyx reported Q2 2026 product revenue of $118.1 million and EPS of approximately $(0.07), both below consensus. The company lowered its full-year 2026 IBSRELA revenue guidance to $350-$370 million from $410-$430 million, citing increased payer utilization-management processes such as additional step edits and more stringent prior authorizations that slowed new-patient starts. Ardelyx also withdrew its long-term $750 million XPHOZAH revenue target while maintaining 2026 XPHOZAH guidance of $110-$120 million. Following the August 6, 2026 after-market release, ARDX shares fell 17.86% on August 7, closing at $4.00. Multiple analysts cut price targets. Levi & Korsinsky, LLP launched an investigation into potential securities law violations on behalf of Ardelyx shareholders, focusing on whether Ardelyx adequately disclosed the payer headwinds before the guidance cut.

Key Actions

90 Ardelyx lowered revenue guidance

80 Ardelyx scheduled earnings call

70 Ardelyx withdrew revenue target

60 Levi & Korsinsky launched investigation Ardelyx

Entities Involved

stock

Ardelyx

Ardelyx is the central company, facing a 17.86% stock drop, lowered guidance, and a securities investigation. Its credibility and future revenue outlook are negatively affected.

Importance 100.0 Sentiment -60.0

priv

Levi & Korsinsky

Levi & Korsinsky is the law firm conducting the investigation, which could lead to securities litigation. The firm benefits from increased business and visibility.

Importance 70.0 Sentiment 20.0

oth

XPHOZAH

XPHOZAH's long-term revenue target was withdrawn, though 2026 guidance was maintained. This signals reduced long-term growth expectations for the product.

Importance 70.0 Sentiment -40.0

per

Joseph E. Levi

Joseph E. Levi is a partner at Levi & Korsinsky and a contact for the investigation. His role is to represent shareholders and potentially lead litigation.

Importance 30.0 Sentiment 10.0

Relationships

Levi & Korsinsky related ↔ Joseph E. Levi

ERGEN INTELLIGENCE

Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard